Five-year follow-up of low-level laser therapy (LLLT) in patients with age-related macular degeneration (AMD)

Koev, K.; Avramov, L.; Borissova, Ekaterina

doi:10.1088/1742-6596/992/1/012061

Cited by 3 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Kaymak et al report reductions in central retinal thickness, resolution of intraretinal fluid, and improvement in diabetic retinopathy severity scale scores following multiwavelength PBM treatment in patients with early stage DME with good vision. Furthermore, other clinical reports support positive effects on edema following PBM treatment in several ocular disease states [7,[21][22][23][24][25]. Across medical indications, and more notably across trials in ophthalmic indications, PBM shows a positive safety profile with no signs of phototoxicity or serious concerns related to treatment [20,22,26].…”

Section: Discussionmentioning

confidence: 98%

Improvement in Central Serous Chorioretinopathy Following Multiwavelength Photobiomodulation Treatment – Case Report

Sachdev

2024

Ophthalmol Ther

View full text Add to dashboard Cite

Introduction Central serous chorioretinopathy (CSCR) is a condition where fluid build-up accumulates underneath the retina, resulting in retinal pigment epithelium (RPE) detachment and vision loss. Irreversible retinal functional and anatomical changes are possible consequences. Research into novel strategies to aid in recovery are of interest. Photobiomodulation (PBM) uses light wavelengths to improve cellular function and shows positive effects in several conditions including those with edema. Methods This prospective case report details a 39-year-old woman with CSCR. Multiwavelength PBM treatment was initiated with the Valeda® Light Delivery System. A series of treatment included nine sessions delivered over 3–5 weeks. Follow-up treatments were conducted. Optical coherence tomography (OCT) imaging and best-corrected visual acuity (BCVA) measures were taken. The patient has been followed for approximately 1 year. Results The patient presented with blurred vision and a BCVA score of 65 letters in the left eye. After 3 weeks of observation, the patient’s vision had further declined two lines on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart to 55 letters. Fluorescein angiography was performed, confirming CSCR diagnosis, and PBM was initiated. PBM treatment improved BCVA and fluid build-up in the RPE within 1 week of treatment (three treatment sessions). Following the full series of treatment (nine PBM treatment sessions), fluid was completely resolved and BCVA scored at 80 letters. The patient had a repeat PBM treatment series ~ 6 months later and has shown stable vision and no fluid present on OCT scan. The patient was seen again ~ 1 year later with continued stable vision and no fluid detection. Conclusions PBM is a non-invasive treatment option that may provide benefit in CSCR to resolve fluid build-up, macular change, and vision loss. Research into PBM as an immediate treatment option for CSCR, especially those with chronic presentations or those posed to have irreversible damage, is warranted to confirm effectiveness.

show abstract

Section: Discussionmentioning

confidence: 98%

Improvement in Central Serous Chorioretinopathy Following Multiwavelength Photobiomodulation Treatment – Case Report

Sachdev

2024

Ophthalmol Ther

View full text Add to dashboard Cite

show abstract

“…38 The light intensities used in photobiomodulation therapy are moderate and non-destructive, with wavelengths between 390 to 700 nm and 780 to 1100 nm, fluences between 0.04 and 50 J/cm 2 and power densities < 100 mW/cm 2.39 Wavelengths in the range of 390 nm to 600 nm are used to treat superficial tissue, while 600 nm to 1100 nm is used to treat deeper tissues. 40 For ophthalmic applications, both light-emitting diodes and lasers have been used to treat retinal disease, [41][42][43][44][45] but so far, only the former has been approved for dry eye treatment purposes.…”

Section: Light Sourcesmentioning

confidence: 99%

Photobiomodulation (low-level light therapy) and dry eye disease

Markoulli

Chandramohan

Papas

2021

Clinical and Experimental Optometry

View full text Add to dashboard Cite

Dry eye disease is one of the most common, chief-complaints presenting in clinical practice, with a prevalence of up to 50%. Evaporative dry eye, as a result of meibomian gland dysfunction, is thought to be the biggest component factor. Treatments for meibomian gland dysfunction aim to restore tear film homoeostasis and include warm compress therapy, eyelid hygiene, in-office meibomian gland expression and lipid-containing, artificial tears. A recent introduction to the in-office treatments available for meibomian gland dysfunction has been low-level light therapy, also known as photobiomodulation. The technique involves applying red, or near infra-red, radiation using lowpower light sources and is suggested to promote tissue repair, decrease inflammation, and relieve pain. This work aims to review the available literature on the efficacy and safety of photobiomodulation in meibomian gland dysfunction and dry eye disease, as well as what is currently known about its mechanism of action.

show abstract

Photobiomodulation use in ophthalmology – an overview of translational research from bench to bedside

Valter,

Tedford,

Eells

et al. 2024

Front. Ophthalmol.

View full text Add to dashboard Cite

Photobiomodulation (PBM) refers to the process in which wavelengths of light are absorbed by intracellular photoacceptors, resulting in the activation of signaling pathways that culminate in biological changes within the cell. PBM is the result of low-intensity light-induced reactions in the cell in contrast to thermal photoablation produced by high-intensity lasers. PBM has been effectively used in the clinic to enhance wound healing and mitigate pain and inflammation in musculoskeletal conditions, sports injury, and dental applications for many decades. In the past 20 years, experimental evidence has shown the benefit of PBM in increasing numbers of retinal and ophthalmic conditions. More recently, preclinical findings in ocular models have been translated to the clinic with promising results. This review discusses the preclinical and clinical evidence of the effects of PBM in ophthalmology and provides recommendations of the clinical use of PBM in the management of ocular conditions.

show abstract

Five-year follow-up of low-level laser therapy (LLLT) in patients with age-related macular degeneration (AMD)

Cited by 3 publications

References 18 publications

Improvement in Central Serous Chorioretinopathy Following Multiwavelength Photobiomodulation Treatment – Case Report

Improvement in Central Serous Chorioretinopathy Following Multiwavelength Photobiomodulation Treatment – Case Report

Photobiomodulation (low-level light therapy) and dry eye disease

Photobiomodulation use in ophthalmology – an overview of translational research from bench to bedside

Contact Info

Product

Resources

About